Chris A. Gentry

876 total citations
40 papers, 682 citations indexed

About

Chris A. Gentry is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Chris A. Gentry has authored 40 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 21 papers in Epidemiology and 10 papers in Pharmacology. Recurrent topics in Chris A. Gentry's work include Antibiotic Use and Resistance (9 papers), Microscopic Colitis (8 papers) and Clostridium difficile and Clostridium perfringens research (8 papers). Chris A. Gentry is often cited by papers focused on Antibiotic Use and Resistance (9 papers), Microscopic Colitis (8 papers) and Clostridium difficile and Clostridium perfringens research (8 papers). Chris A. Gentry collaborates with scholars based in United States and Belgium. Chris A. Gentry's co-authors include Riley J. Williams, Keith A. Rodvold, Mark M. Huycke, Leonard N. Slater, D. J. Flournoy, Ronald A. Greenfield, Richard Novák, Odin Naderer, Ronald C. Hershow and Matthew F. Wack and has published in prestigious journals such as Clinical Infectious Diseases, Critical Care Medicine and Clinical Microbiology and Infection.

In The Last Decade

Chris A. Gentry

37 papers receiving 646 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris A. Gentry United States 15 327 324 141 118 104 40 682
Jeannie D. Chan United States 20 267 0.8× 303 0.9× 140 1.0× 153 1.3× 133 1.3× 53 1.1k
Shravan Kethireddy United States 12 423 1.3× 260 0.8× 125 0.9× 146 1.2× 98 0.9× 23 714
Daniel Curcio United States 16 436 1.3× 265 0.8× 158 1.1× 87 0.7× 123 1.2× 50 866
Mervyn Mer South Africa 18 329 1.0× 230 0.7× 61 0.4× 169 1.4× 122 1.2× 46 919
Lala M. Dunbar United States 16 465 1.4× 396 1.2× 258 1.8× 104 0.9× 111 1.1× 22 1.1k
Sumathi Nambiar United States 17 241 0.7× 188 0.6× 241 1.7× 75 0.6× 97 0.9× 37 911
Shruti K. Gohil United States 13 407 1.2× 275 0.8× 88 0.6× 136 1.2× 127 1.2× 35 811
S. Diamantis France 15 208 0.6× 181 0.6× 101 0.7× 68 0.6× 160 1.5× 73 596
Elizabeth Dodds Ashley United States 19 525 1.6× 500 1.5× 96 0.7× 81 0.7× 256 2.5× 66 1.0k
Kathleen Chiotos United States 17 356 1.1× 296 0.9× 175 1.2× 105 0.9× 159 1.5× 65 1.1k

Countries citing papers authored by Chris A. Gentry

Since Specialization
Citations

This map shows the geographic impact of Chris A. Gentry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris A. Gentry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris A. Gentry more than expected).

Fields of papers citing papers by Chris A. Gentry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris A. Gentry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris A. Gentry. The network helps show where Chris A. Gentry may publish in the future.

Co-authorship network of co-authors of Chris A. Gentry

This figure shows the co-authorship network connecting the top 25 collaborators of Chris A. Gentry. A scholar is included among the top collaborators of Chris A. Gentry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris A. Gentry. Chris A. Gentry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Gentry, Chris A., et al.. (2023). Staphylococcus aureus bacteraemia treatment outcomes in patients receiving ticagrelor vs a propensity-matched cohort receiving clopidogrel. International Journal of Antimicrobial Agents. 61(4). 106743–106743.
4.
Gentry, Chris A., et al.. (2023). Propensity-matched analysis of the protective effect of ticagrelor versus clopidogrel on the risk of developing Staphylococcus aureus bacteremia. International Journal of Antimicrobial Agents. 61(4). 106752–106752. 3 indexed citations
5.
Gentry, Chris A., et al.. (2021). Continued decline in the prevalence of the Clostridioides difficile BI/NAP1/027 strain across the United States Veterans Health Administration. Diagnostic Microbiology and Infectious Disease. 100(2). 115308–115308. 3 indexed citations
6.
7.
Gentry, Chris A., et al.. (2020). Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. The Lancet Rheumatology. 2(11). e689–e697. 29 indexed citations
8.
Gentry, Chris A., et al.. (2018). Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Clinical Microbiology and Infection. 25(8). 987–993. 24 indexed citations
9.
Gentry, Chris A. & Riley J. Williams. (2017). A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam. International Journal of Antimicrobial Agents. 49(3). 333–338. 2 indexed citations
10.
Gentry, Chris A. & Riley J. Williams. (2015). Increased antimicrobial susceptibility rates for Pseudomonas aeruginosa bloodstream isolates across the Veterans Affairs Healthcare System. Diagnostic Microbiology and Infectious Disease. 82(3). 215–221. 5 indexed citations
11.
Gentry, Chris A., et al.. (2013). A Comparison of Adverse Drug Reactions Between High- and Standard- Dose Trimethoprim-Sulfamethoxazole in the Ambulatory Setting. Current Drug Safety. 8(2). 114–119. 20 indexed citations
12.
Benefield, Russell J, Douglas A. Drevets, Mark M. Huycke, & Chris A. Gentry. (2012). A Multicenter Evaluation of the Safety of Drotrecogin Alfa (Activated) in Patients with Baseline Bleeding Precautions. Current Drug Safety. 7(1). 3–7. 4 indexed citations
13.
Gentry, Chris A., et al.. (2010). Analysis of Linezolid‐Associated Hematologic Toxicities in a Large Veterans Affairs Medical Center. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(9). 895–903. 27 indexed citations
14.
Flournoy, D. J., et al.. (2000). Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. American Journal of Infection Control. 28(3). 244–250. 33 indexed citations
15.
Gentry, Chris A., Keith A. Rodvold, Richard Novák, Ronald C. Hershow, & Odin Naderer. (1997). Retrospective Evaluation of Therapies for Staphylococcus aureus Endocarditis. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(5). 990–997. 61 indexed citations
16.
Rodvold, Keith A., et al.. (1995). Bayesian Forecasting of Serum Vancomycin Concentrations in Neonates and Infants. Therapeutic Drug Monitoring. 17(3). 239–246. 27 indexed citations
17.
Gentry, Chris A. & Keith A. Rodvold. (1995). How Important Is Therapeutic Drug Monitoring in the Prediction and Avoidance of Adverse Reactions?. Drug Safety. 12(6). 359–363. 5 indexed citations
18.
Gentry, Chris A., Frank P. Paloucek, & Keith A. Rodvold. (1994). Prediction of Acetaminophen Concentrations in Overdose Patients Using a Bayesian Pharmacokinetic Model. Journal of Toxicology Clinical Toxicology. 32(1). 17–30. 4 indexed citations
19.
Gentry, Chris A., Keith A. Rodvold, & Joseph Bertino. (1993). Methods of Minimising the Cost of Aminoglycoside Therapy to Hospitals. PharmacoEconomics. 3(3). 228–243. 6 indexed citations
20.
Rodvold, Keith A., et al.. (1993). Prediction of GentamicinConcentrations in Neonates andInfants Using a BayesianPharmacokinetic Model. Developmental Pharmacology and Therapeutics. 20(3-4). 211–219. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeannie D. Chan Breakdown of academic impact, for papers by Shravan Kethireddy Breakdown of academic impact, for papers by Daniel Curcio Breakdown of academic impact, for papers by Mervyn Mer Breakdown of academic impact, for papers by Lala M. Dunbar Breakdown of academic impact, for papers by Sumathi Nambiar Breakdown of academic impact, for papers by Shruti K. Gohil Breakdown of academic impact, for papers by S. Diamantis Breakdown of academic impact, for papers by Elizabeth Dodds Ashley Breakdown of academic impact, for papers by Kathleen Chiotos
Rankless by CCL
2026